

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 48582

Manuscript Type: CASE REPORT

Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report

Cakir OO. Refractory pouchitis and vedolizumab

Ozlem Ozer Cakir

Abstract

BACKGROUND

Refractory pouchitis is a common cause of pouch failure, which may require surgical excision of the pouch or permanent diversion. We aimed to show the effect of Vedolizumab on treatment of the patient with refractory pouchitis.

CASE SUMMARY

A 32-year-old male with pancolonic ulcerative colitis since the age of 25 with primary failure of infliximab and mesalamine and intolerance of azathioprine, underwent a total proctocolectomy with ileal pouch-anal anastomosis in 2012. He developed chronic diarrhea in 2014, which was watery, thirty per day and accompanied with blood, mucus affecting his quality of life.

Match Overview

| | | |
|---|---|----|
| 1 | Crossref 53 words Mohamad Yousef, Fazia Mir, Edward Partyka, Veysel Tahan. "Successful Treatment of Chronic Refractory Pouchitis W ... | 4% |
| 2 | Crossref 27 words M. Coletta, M. Paroni, F. Caprioli. "Successful Treatment Wit h Vedolizumab in a Patient With Chronic Refractory Poucl ... | 2% |
| 3 | Internet 15 words crawled on 07-Mar-2019 www.wjgnet.com | 1% |
| 4 | Crossref 14 words Freeha Khan, Xian-Hua Gao, Amandeep Singh, Jessica J... Philpott, Bo Shen. "Vedolizumab in the treatment of Crohn's | 1% |
| 5 | Internet 12 words crawled on 19-Mar-2019 his.org.uk | 1% |



All

Images

Videos

翻译成中文

关闭取词

26,000 Results

Any time ▼

Efficacy of Vedolizumab in Patients with Antibiotic and ...

https://www.researchgate.net/publication/311525035_Efficacy_of_Vedolizumab_in_Patients...

Efficacy of Vedolizumab in Patients with Antibiotic and Anti-tumor Necrosis Alpha Refractory Pouchitis Article in Inflammatory Bowel Diseases 23(1):1 - ...

Vedolizumab in the treatment of Crohn's disease of the ...

<https://academic.oup.com/gastro/article/6/3/184/5043123> ▼

Jun 22, 2018 · The mean age at the time of pre-colectomy diagnosis of UC was 25.0 ± 11.5 years. The mean current age was 41.0 ± 12.1 years, nine (75.0%) were female, **three** (25.0%) had smoked and eight (66.7%) had used **anti-tumor necrosis factor** agents prior to **vedolizumab** use. The mean duration of vedolizumab use was 1.0 ± 6.4 years.

Cited by: 3

Author: Freeha Khan, Xian-Hua Gao, Amandeep ...

Publish Year: 2018

Author: Khan, Freeha

(PDF) Successful treatment of chronic refractory pouchitis ...

https://www.researchgate.net/publication/318357874_Successful_treatment_of_chronic...

Successful **treatment** of chronic **refractory** pouchitis with **vedolizumab** Article (PDF Available) in International Journal of Colorectal Disease 32(4) · July 2017 with 93 Reads DOI: 10.1007/s00384 ...

Infliximab in refractory pouchitis complicated by fistulae ...

<https://onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2036.2003.01535.x>

As infliximab has been successfully used for the treatment of **patients with refractory Crohn's disease** of the ileo-anal pouch, 18 and as high **tumour necrosis factor-alpha** (TNF- α) expression occurs in the **ileal mucosa** during pouchitis, 4 the use of infliximab in refractory pouchitis following IPAA for **ulcerative colitis** appears to be reasonable.

Cited by: 84

Author: A. Viscido, F. I. Habib, A. Kohn, C. Papi, ...

Publish Year: 2003



国内版

国际版

Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor



All

Images

Videos

翻译成中文

开启取词

26,000 Results

Any time ▾

Efficacy of Vedolizumab in Patients with Antibiotic and ...

https://www.researchgate.net/publication/311525035_Efficacy_of_Vedolizumab_in_Patients...

Request PDF on ResearchGate | **Efficacy of Vedolizumab in Patients with Antibiotic and Anti-tumor Necrosis Alpha Refractory Pouchitis** | Refractory pouchitis is a risk factor for pouch failure and ...

(PDF) Successful treatment of chronic refractory pouchitis ...

https://www.researchgate.net/publication/318357874_Successful_treatment_of_chronic...

Successful **treatment** of chronic refractory pouchitis with vedolizumab Article (PDF Available) in International Journal of Colorectal Disease 32(4) · July 2017 with 93 Reads DOI: 10.1007/s00384 ...

Vedolizumab in the treatment of Crohn's disease of the ...

<https://academic.oup.com/gastro/article/6/3/184/5043123> ▾

Jun 22, 2018 · Anti-tumor necrosis factor agent, Crohn's disease, ileal pouch, restorative proctocolectomy, vedolizumab Introduction Restorative proctocolectomy with ileal pouch anal anastomosis (IPAA) is the treatment of choice for medically refractory ulcerative colitis (UC), colitis-associated dysplasia and familial adenomatous polyposis (FAP) [1].

Cited by: 3 Author: Freeha Khan, Xian-Hua Gao, Amandeep ...

Publish Year: 2018 Author: Khan, Freeha

Efficacy of Vedolizumab Induction and Maintenance Therapy ...

[https://www.cghjournal.org/article/S1542-3565\(16\)30655-3/fulltext](https://www.cghjournal.org/article/S1542-3565(16)30655-3/fulltext)

We analyzed data from 1 of these trials to determine the effects of vedolizumab therapy in patients with UC, based on past exposure to anti-tumor necrosis factor- α (TNF) antagonists. **Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists** - Clinical Gastroenterology and Hepatology

Cited by: 59 Author: Brian G. Feagan, David T. Rubin, Silvio D...

Publish Year: 2017

Infliximab in refractory pouchitis complicated by fistulae ...

<https://onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2036.2003.01535.x>

As infliximab has been successfully used for the treatment of patients with refractory Crohn's disease of the ileo-anal pouch, 18 and as high tumour necrosis factor- α (TNF- α) expression occurs in the ileal mucosa during pouchitis, 4 the use of infliximab in refractory pouchitis following IPAA for ulcerative colitis appears to be reasonable.

Cited by: 84 Author: A. Viscido, F. I. Habib, A. Kohn, C. Papi, A...

Publish Year: 2003

Cost-Effectiveness Analysis of Crohn's Disease Treatment ...

<https://link.springer.com/article/10.1007/s40273-018-0653-2> ▾

Apr 17, 2018 The inclusion of vedolizumab or ustekinumab in the treatment of CD will result in its use among patients who cannot use anti-TNFs because of failure of therapy, those who would have another